Evidence map›Paper›PMID 35118579›Full record

ArticleJournal of cancer survivorship : research and practice2023

Future steps in cardio-oncology-a national multidisciplinary survey among healthcare professionals in the Netherlands.

Yvonne Koop, Arco J Teske, Iris Wanders, Hanneke Meijer, J H A M Hans Kaanders, Olivier C Manintveld, H Carlijne Hassing, Hester Vermeulen, Angela H E M Maas, Dick-Johan van Spronsen and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of cancer survivorship : research and practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Yvonne KoopDepartment of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands. Yvonne.Koop@radboudumc.nl.ORCID http://orcid.org/0000-0001-6150-0859
Arco J TeskeDepartment of Cardiology, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands.
Iris WandersDepartment of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands.
Hanneke MeijerDepartment of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
J H A M Hans KaandersDepartment of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
Olivier C ManintveldDepartment of Cardiology, Erasmus University Medical Center, Rotterdam, The Netherlands.
H Carlijne HassingDepartment of Cardiology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Hester VermeulenScientific Institute for Quality of Healthcare, Radboud University Medical Center, Nijmegen, The Netherlands.
Angela H E M MaasDepartment of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands.
Dick-Johan van SpronsenDepartment of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
Femke AtsmaScientific Institute for Quality of Healthcare, Radboud University Medical Center, Nijmegen, The Netherlands.
Saloua El MessaoudiDepartment of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands.
Radboud University Nijmegen · NLErasmus MC · NLHAN University of Applied Sciences · NLUtrecht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe awareness of cancer therapy-related adverse cardiac effects is fueled by recent literature on cardiotoxicity incidence and detection strategies. Although this influences the sense of urgency, in current practice, cardiotoxicity monitoring and treatment is not structurally performed. With this study, we aimed to evaluate current perspectives on cardio-oncology and to assess needs, ultimately to determine an agenda for improvements in current practice. MATERIAL AND

methodsA national multidisciplinary 36-question survey was conducted. The survey was developed by a multidisciplinary team, theoretically based on an implementation checklist and distributed by email, through cardiology and oncology societies as well as social media.

resultsOne hundred ninety professionals completed the survey, of which 66 were cardiologists, 66 radiation oncologists, and 58 medical oncologists and hematologists. Many professionals were unaware of their specialisms' cardio-oncology guidelines: 62.1% of cardiologists and 29.3% of the hematologists and medical oncologists respectively. Many cardiologists (N = 46; 69.7%), radiation oncologists (N = 45; 68.2%), and hematologists and medical oncologists (N = 38; 65.5%) expressed that they did not have sufficient knowledge to treat cardio-oncology patients and would either refer a patient or aspire to gain more knowledge on the topic.

conclusionThe field of cardio-oncology is advancing rapidly, with progress in stratification and detection strategies leading to the development of new guidelines and consensus statements. However, the application of these guidelines in current practice appears to be lagging. Professionals express a need for additional training and a practical guideline including risk stratification, monitoring, and treatment strategies. Multidisciplinary discussion and consensus on cardio-oncology care is vital to improve implementation of cardio-oncology guidelines, ultimately to improve cardiac care for oncology patients.

Indexed as

Cancer SurvivorsNeoplasmsCardiotoxicityDelivery of Health CareHumansNetherlandsCancer therapy–related cardiac dysfunctionCardio-oncologyGuideline implementationHealthcare professionalsQuality of careSurvey

Identifiers

PMID35118579
PMCPMC10285002
OpenAlexW4210490670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.